Disease-Free Survival
FIG 2. · Panel DFS_Probability_vs._Time
Panel DFS_Probability_vs._Time 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Robert J Motzer, Axel Bex, Paul Russo, Yoshihiko Tomita, Hernan Javier Cutuli, Carlos Rojas, Marine Gross-Goupil, Giovanni Schinzari, Bohuslav Melichar, Philippe Barthélémy, Abraham Ruiz Garcia, Jeffrey Sosman, Marc-Oliver Grimm, Jeffrey C Goh, Cristina Suarez, Christian K Kollmannsberger, Suresh G Nair, Brian M Shuch, Jian Huang, Burcin Simsek, Julia Spiridigliozzi, Chung-Wei Lee, Maximiliano van Kooten Losio, Viktor Grünwald
J Clin Oncol 43(2) 189-200
PURPOSE: CheckMate 914 is a two-part, randomized phase III trial evaluating adjuvant nivolumab plus ipilimumab (part A) or adjuvant nivolumab monotherapy (part B) versus placebo in mutually exclusive populations of patients with localized renal cell carcinoma (RCC) at high risk of postnephrectomy recurrence. Part A showed no disease-free survival (DFS) benefit for adjuvant nivolumab plus ipilimumab versus placebo. We report results from part B. METHODS: Patients were randomly assigned (2:1:1) to nivolumab (240 mg once every 2 weeks for up to 12 doses), placebo, or nivolumab (240 mg once every 2 weeks for up to 12 doses) plus ipilimumab (1 mg/kg once every 6 weeks for up to four doses). The planned treatment duration was 24 weeks (approximately 5.5 months). The primary end point was DFS per blinded independent central review (BICR) for nivolumab versus placebo; safety was a secondary end point. RESULTS: Overall, 825 patients were randomly assigned to nivolumab (n = 411), placebo (n = 208), or nivolumab plus ipilimumab (n = 206). With a median follow-up of 27.0 months (range, 18.0-42.4), the primary end point of improved DFS per BICR with nivolumab versus placebo was not met (hazard ratio [HR], 0.87 [95% CI, 0.62 to 1.21]; P = .40); the median DFS was not reached in either arm, and 18-month DFS rates were 78.4% versus 75.4%. The HR for DFS per investigator was 0.80 (95% CI, 0.58 to 1.12; P = .19). Grade 3-4 all-cause adverse events (AEs) occurred in 17.2%, 15.0%, and 28.9% of patients with nivolumab, placebo, and nivolumab plus ipilimumab, respectively. Any-grade treatment-related AEs led to discontinuation in 9.6%, 1.0%, and 28.4%, respectively. CONCLUSION: Part B of CheckMate 914 did not meet the primary end point of improved DFS for nivolumab versus placebo in patients with localized RCC at high risk of postnephrectomy recurrence.
2 个 Figure · 4 个 KM 面板
DFS per BICR in the overall ITT population for nivolumab versus placebo. DFS was estimated in all randomly assigned patients and defined as the time from random assignment to the development of local disease recurrence, distant metastasis, or death, whichever came first. BICR, blinded independent central review; DFS, disease-free survival; HR, hazard ratio; ITT, intention-to-treat; NE, not estimable; NR, not reached.
FIG 2. · Panel DFS_Probability_vs._Time
Panel DFS_Probability_vs._Time 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
DFS per BICR in pooled subgroups of interest with sarcomatoid features (A), PD-L1 expression ≥1% (B), or pT4, any grade (N0M0) or any pT, any grade (N1M0) staging (C). Ad hoc analyses were conducted using pooled data from parts A and B of the study to compare DFS per BICR with immunotherapy (nivolumab plus ipilimumab in part A and either nivolumab or nivolumab plus ipilimumab in part B) versus placebo (from parts A and B) in select subgroups of patients. DFS was estimated in all randomly assigned patients and defined as the time from random assignment to the development of local disease recurrence, distant metastasis, or death, whichever came first. PD-L1 testing was performed locally (Labcorp) using a validated tumor proportion score–based PD-L1 immunohistochemical assay (Dako PD-L1 IHC 28-8 pharmDx). BICR, blinded independent central review; DFS, disease-free survival; HR, hazard ratio; NE, not estimable; NR, not reached.
FIG 4. · Panel A
Panel A 是同一 FIG 4. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIG 4. · Panel B
Panel B 是同一 FIG 4. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIG 4. · Panel C
Panel C 是同一 FIG 4. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。